Contralateral but not systemic administration of the κ‐opioid agonist U‐50,488H induces anti‐nociception in acute hindpaw inflammation in rats
- 29 January 2001
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 132 (1) , 252-258
- https://doi.org/10.1038/sj.bjp.0703782
Abstract
1. The anti-nociceptive effects of contralateral administration of kappa-opioid agonist U-50,488H were investigated in rats. 2. Inflammation was induced by unilateral injection of 1% carrageenan into the right hindpaw. Prior to carrageenan injection, U-50,488H or saline was administered into the left hindpaw. Withdrawal responses to mechanical and heat stimulation and oedema levels were evaluated at 3, 6 and 24 h post-carrageenan injection. 3. The results showed that the inflammatory effect of 1% carrageenan peaked after 6 h with bilateral decreases in withdrawal latencies and ipsilateral oedema formation. 4. Contralateral treatment with 0.01, 0.05, 0.3 and 2 mg of U-50,488H attenuated nociceptive reflexes to mechanical stimulation on the inflamed side at 6 h. The anti-nociceptive effect of contralateral treatment was dose-dependent at 3 and 24 h. The hindpaw withdrawal latencies to heat stimulation were prolonged at 3 and 24 h after contralateral treatment with 0.3 mg U-50,488H. No effect on inflammatory oedema formation was observed, except for a decrease at 3 h after treatment with 2 mg of U-50,488H. 5. Sciatic nerve denervation on the contralateral side abolished the anti-nociceptive effects of U-50,488H (0.3 and 2 mg). In contrast, contralateral injection of 1 mg morphine prolonged paw latencies in denervated rats. 6. Both co-administration of the peripherally selective opioid antagonist naloxone methiodide with 0.3 mg U-50,488H, and alternatively, systemic administration of 0.3 mg U-50,488H reversed the anti-nociceptive effects induced by contralateral injection of U-50,488H. 7. Taken together, our findings indicate that the contralateral administration of U-50,488H attenuates nociceptive behaviour resulting from acute inflammation. The effect is mediated via peripheral neuronal kappa-opioid receptors and, possibly, spinal cord mechanisms, suggesting a new treatment approach for acute inflammatory conditions.Keywords
This publication has 26 references indexed in Scilit:
- Tachykinins and calcitonin gene-related peptide (CGRP) as co-transmitters released from peripheral endings of sensory nervesPublished by Elsevier ,2000
- Contralateral but not systemic administration of bupivacaine reduces acute inflammation in the rat hindpawSomatosensory & Motor Research, 2000
- Unilateral injection of calcitonin gene‐related peptide (CGRP) induces bilateral oedema formation and release of CGRP‐like immunoreactivity in the rat hindpawBritish Journal of Pharmacology, 1998
- No tolerance to peripheral morphine analgesia in presence of opioid expression in inflamed synovia.Journal of Clinical Investigation, 1996
- Local analgesic effect of endogenous opioid peptidesThe Lancet, 1993
- Peripheral Mechanisms of Opioid AnalgesiaAnesthesia & Analgesia, 1993
- Multiple opioid systems and painPain, 1986
- Heterogeneous sensitivity of cultured dorsal root ganglion neurones to opioid peptides selective for µ - and δ -opiate receptorsNature, 1982
- Pain Mechanisms: A New TheoryScience, 1965
- EXPERIMENTAL EVIDENCE ON THE NATURE OF CUTANEOUS HYPERALGESIAJournal of Clinical Investigation, 1950